Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
THRB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
THRB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of THRB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TAS1R2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TAS1R2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TAS1R2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TAFA4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TAFA4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TAFA4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TAFA5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TAFA5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TAFA5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TAFA2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TAFA2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TAFA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TAFA3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TAFA3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TAFA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SPAG17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SPAG17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SPAG17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SORL1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SORL1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SORL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TAAR8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TAAR8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TAAR8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TAFA1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TAFA1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TAFA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SPAG16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SPAG16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SPAG16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SOCS6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SOCS6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SOCS6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →